Perspectives On 340B: An Interview With Lilly’s Derek Asay
Lilly is one of the more active manufacturers when it comes to overseeing provider compliance with rules for the 340B drug discount program. Derek Asay, Lilly senior director of government strategy for federal accounts, spoke to “The Pink Sheet” about the company’s approach.
You may also be interested in...
HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.
The ranking member on the Senate Judiciary Committee sends a letter to the University of Alabama Hospital seeking details on how it has changed the admission status and treatment of patients to get 340B drug discounts for patients who would not have been eligible otherwise.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.